gene

SNCA

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SNCA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2896Connections

1Hypotheses

6Analyses

50Outgoing

50Incoming

Summary

SNCA is a gene implicated in neurodegeneration research. Key relationships include: interacts with, associated with, activates. Associated with AD, ALI, ALS. Connected to 983 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	SNCA
Full Name	Alpha-Synuclein
Chromosome	4q22.1
Protein Type	Structural Protein
Target Class	Structural Protein
Function	Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation
Mechanism of Action	Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation
Primary Expression	Substantia nigra, Cerebral cortex, Presynaptic terminals
Druggability	Medium (0.49)
Clinical Stage	Phase II
Pathways	Akt, Alpha-Synuclein, Autophagy, Cell Cycle, Epigenetic
UniProt ID	P37840
NCBI Gene ID	6622
Ensembl ID	ENSG00000145335
OMIM	163890
GeneCards	SNCA
Human Protein Atlas	SNCA
Associated Diseases	AD, ALI, ALS, ALZHEIMERS_DISEASE, Aging, Alpha-Synucleinopathies
Known Drugs/Compounds	Rna G-Quadruplex, Phosphatidic Acid, RAPAMYCIN, ASO, PBT434, D-520
Interactions	DRD2, HSPA1A, DNMT1, TLR4, FAM134B, LC3
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Neuronal Subtype-Specific Alpha-Synuclein Expressi
KG Connections	2895 knowledge graph edges
Databases	GeneCards HPA STRING

🧬 3D Structure: SNCA — PDB 1XQ8 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    SNCA["SNCA"] -->|"modulates"| calcium["calcium"]
    SNCA["SNCA"] -->|"associated"| neurodegeneration["neurodegeneration"]
    SNCA["SNCA"] -->|"interacts"| DRD2["DRD2"]
    SNCA["SNCA"] -->|"interacts"| HSPA1A["HSPA1A"]
    SNCA["SNCA"] -->|"interacts"| DNMT1["DNMT1"]
    SNCA["SNCA"] -->|"encodes"| alpha_synuclein["alpha_synuclein"]
    DRD2_1["DRD2"] -->|"interacts"| SNCA["SNCA"]
    HSPA1A_2["HSPA1A"] -->|"interacts"| SNCA["SNCA"]
    DNMT1_3["DNMT1"] -->|"interacts"| SNCA["SNCA"]
    TLR4["TLR4"] -->|"interacts"| SNCA["SNCA"]
    style SNCA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (1509)

Target	Relation	Type	Str
dementia with Lewy bodies	implicated_in	disease	1.00
ALPHA_SYNUCLEIN	encodes	protein	1.00
Dementia	associated_with	disease	1.00
Α-SYNUCLEIN	encodes	protein	0.99
Lewy Bodies	biomarker_for	biomarker	0.98
Lewy body pathology	associated_with	phenotype	0.98
Lewy Bodies	involved_in	phenotype	0.95
Parkinson Disease	associated_with	disease	0.95
Inflammatory Response	associated_with	process	0.95
CD4 T Cell Activation	activates	process	0.95
Neuronal α-synuclein Disease	risk_factor_for	disease	0.95
Microglial Autophagy	associated_with	process	0.95
Alpha-Synucleinopathies	causes	disease	0.95
Parkinson's Disease with Dementia	associated_with	disease	0.95
Lewy Bodies	associated_with	biomarker	0.95
MTOR	activates	protein	0.95
Lewy Bodies	contributes_to	biomarker	0.95
Parkinson Disease	risk_factor_for	disease	0.95
MIRO1	upregulates	protein	0.95
Parkinson'S Disease With Dementia	involved_in	disease	0.95
Amyloid Formation	involved_in	process	0.95
alpha-synuclein aggregation	involved_in	process	0.95
Dementia with Lewy Bodies	implicated_in	disease	0.95
Multiple System Atrophy	implicated_in	disease	0.95
Lewy bodies	causes	phenotype	0.95
Dementia With Lewy Bodies	implicated_in	disease	0.95
Parkinson	associated_with	disease	0.95
Als	associated_with	disease	0.95
alpha-synuclein	produces	protein	0.95
PARKINSON'S DISEASE	associated_with	gene	0.95
Parkinson's Disease	associated_with	disease	0.95
Parkinson's Disease	causes	disease	0.95
Parkinson's Disease	risk_factor_for	disease	0.95
Parkinson's Disease	involved_in	disease	0.95
Parkinson's Disease	component_of	disease	0.95
ALPHA-SYNUCLEIN	encodes	protein	0.95
Parkinson'S Disease	associated_with	disease	0.95
Parkinson'S Disease	causes	disease	0.95
Parkinson'S Disease	biomarker_for	disease	0.95
PARKINSON'S DISEASE	involved_in	disease	0.95
Synucleinopathies	involved_in	disease	0.95
Synucleinopathies	causes	disease	0.95
Parkinson'S Disease	involved_in	disease	0.95
Lewy Body Formation	involved_in	process	0.95
Synucleinopathies	implicated_in	disease	0.95
Parkinson'S Disease	implicated_in	disease	0.95
Microglia	interacts_with	cell_type	0.94
LAG3	interacts_with	protein	0.93
Lewy Body Aggregates	involved_in	mechanism	0.92
Neuroinflammation	promotes	process	0.92

Incoming (1387)

Source	Relation	Type	Str
TAU	associated_with	gene	1.00
MICROGLIA	associated_with	gene	1.00
AMYLOID	associated_with	gene	1.00
PARKINSON'S DISEASE	associated_with	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
D-520	targets	drug	0.95
Rna G-Quadruplex	promotes	compound	0.95
ATC161	degrades	drug	0.95
AUTOTAC	targets	mechanism	0.95
Short-Chain Fatty Acids	modulates	compound	0.95
LAG3	binds	gene	0.95
Rmab38E2-Scfv8D3	targets	drug	0.95
Microglia	cleaves	cell_type	0.95
Microglia	degrades	cell_type	0.95
Autophagy-Lysosomal Pathway	interacts_with	pathway	0.92
Microglial Autophagy Disruption	causes	process	0.90
PBT434	inhibits	compound	0.90
UB-312	targets	drug	0.90
AFFITOPE PD01A	targets	drug	0.90
PD03A	targets	drug	0.90
ACI-7104.056	targets	drug	0.90
Prasinezumab	targets	drug	0.90
Cinpanemab	targets	drug	0.90
MEDI1341	targets	drug	0.90
Lu Af82422	targets	drug	0.90
Chaperone-Mediated Autophagy	mediates	pathway	0.90
Impaired Degradation	causes	mechanism	0.90
Csga	associated_with	protein	0.90
SncaEnh+37	regulates	structure	0.90
SDA-2026-04-01-gap-20260401-225155	targets	analysis	0.90
brain-derived extracellular vesicles	mediates	compound	0.90
Lactococcus Lactis Mg1363-Pmg36E-Glp-1	associated_with	drug	0.90
Autophagy	degrades	process	0.90
Antisense Oligonucleotide Therapy	downregulates	drug	0.90
NEURON	contributes_to	cell_type	0.90
ANTISENSE OLIGONUCLEOTIDES	downregulates	drug	0.90
Synucleinopathies	associated_with	disease	0.90
PAP	co-deleted/mutated	gene	0.90
h-072b2f5d	targets_gene	hypothesis	0.90
h-74777459	targets_gene	hypothesis	0.90
h-2e7eb2ea	targets_gene	hypothesis	0.90
h-b7ab85b6	targets_gene	hypothesis	0.90
Motor Deficits	associated_with	phenotype	0.88
ASO	inhibits	drug	0.87
SQSTM1	binds	protein	0.85
Rotenone	upregulates	compound	0.85
PLK2	phosphorylates	entity	0.85
Iron	mediates	biomarker	0.85
Astrocyte Phagocytosis	involved_in	phenotype	0.85

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Neuronal Subtype-Specific Alpha-Synuclein Expression Normali	0.382	neurodegeneration	Which cell types show the most significa

Mentioning Analyses (6)

Scientific analyses that reference this entity

Related Papers (12)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Meta-analysis of mRNA dysregulation associated with Parkinson's disease and othe [PMID:41183391]	Lin Aung T, Aung YW, Shi X	Biomed Phys Eng Express	2026	1
A human striatal-midbrain assembloid model of alpha-synuclein propagation. [PMID:40919647]	Tran HD, Shin MK, Yeo XY, Jung S, Junaid	Brain	2026	0
Neuronal titration of Snca via enhancer disruption mitigates disease onset in a [PMID:41496593]	Boyd RJ, Kho AR, McClymont SA, Loftus SK	Brain	2026	0
Perampanel Blocks Transsynaptic α-Synuclein Propagation and Neurodegeneration in [PMID:41508763]	Ueda J, Uemura N, Chang J, Hirato T, Ish	Mov Disord	2026	0
Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 p [PMID:41574889]	Fraser KB, Mirelman A, Mabrouk OS, Omer	J Parkinsons Dis	2026	0
Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in [PMID:41635116]	Wang Y, Lipton SA	J Neurochem	2026	0
SNCA triplication disrupts proteostasis and extracellular architecture prior to [PMID:41698927]	Statoulla E, Zafeiri M, Chalkiadaki K, V	NPJ Parkinsons Dis	2026	0
Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's dise [PMID:41730496]	Panda SP, Saraswat N, Singh V	Neuroscience	2026	0
Degradation of alpha-synuclein/SNCA mRNA by RNautophagy. [PMID:41747943]	Kabuta C, Hakuno F, Kataoka N, Takahashi	Neurochem Int	2026	0
An update on the monogenic causes of Parkinson's disease: Impact on patient stra [PMID:41759745]	Asmi S, Krishnan A, Alexander SM, Mohame	Ageing Res Rev	2026	0
N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in P [PMID:41766663]	Song P, Chen C, Franchini R, Duong B, Wa	J Clin Invest	2026	0
Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRI [PMID:41905621]	["Singh R", "Maity P", "Jaiswal C"]	Neurochemistry international	2026	0

SNCA

Understanding Entity Pages

Summary

Wiki Pages (21)

SNCA — Alpha-Synuclein

Novel Therapy Index

Parkinson's Disease

Device Therapies Comparison for CBS/PSP

Alpha-Synuclein Pathology

PD Combination Therapy Matrix

Pathway Diagram

Outgoing (1509)

Incoming (1387)

Targeting Hypotheses (1)

Mentioning Analyses (6)

How does engineered C. butyricum cross the blood-brain barrier to directly bind

Which cell types show the most significant expression changes for neurodegenerat

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Digital biomarkers and AI-driven early detection of neurodegeneration

4R-tau strain-specific spreading patterns in PSP vs CBD

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Related Papers (12)

SNCA

Understanding Entity Pages

Summary

Wiki Pages (21)

SNCA — Alpha-Synuclein

Novel Therapy Index

Parkinson's Disease

Device Therapies Comparison for CBS/PSP

Alpha-Synuclein Pathology

PD Combination Therapy Matrix

Neuroresilience Mechanisms and Evidence

neuroinflammation

NRF2 Oxidative Stress Pathway

Multiple System Atrophy

PD Cure Roadmap

Synucleinopathy Mechanism

oxidative-stress-comparison

Prion vs Tau/Alpha-Synuclein Propagation: Mechanistic Comparison

rankings

TRA2B Protein - Transformer-2 Beta

substantia-nigra

Synaptic Vesicle Trafficking in Parkinson's Disease

Epigenetic Dysregulation in Neurodegeneration

Epigenetic Dysregulation Comparison -- AD/PD/ALS/FTD/HD

Alpha-Synuclein Prion-Like Spreading Mechanisms in Parkinson's Disease

Pathway Diagram

Outgoing (1509)

Incoming (1387)

Targeting Hypotheses (1)

Mentioning Analyses (6)

How does engineered C. butyricum cross the blood-brain barrier to directly bind

Which cell types show the most significant expression changes for neurodegenerat

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Digital biomarkers and AI-driven early detection of neurodegeneration

4R-tau strain-specific spreading patterns in PSP vs CBD

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Related Papers (12)